ARAY Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -23.08% compared to Accuray, Inc.'s net margin of -12425.36%. Accuray, Inc.'s return on equity of -33.8% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Accuray, Inc. has a consensus price target of $3.88, signalling upside risk potential of 293.2%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than Accuray, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Accuray, Inc..

Accuray, Inc. has a beta of 1.065, which suggesting that the stock is 6.549% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $93.9M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Accuray, Inc.'s net income of -$21.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.24x versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -23.08% compared to Accuray, Inc.'s net margin of -862.39%. Accuray, Inc.'s return on equity of -33.8% beat VolitionRX Ltd.'s return on equity of --.

Accuray, Inc. has a consensus price target of $3.88, signalling upside risk potential of 293.2%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Accuray, Inc., analysts believe VolitionRX Ltd. is more attractive than Accuray, Inc..

Accuray, Inc. has a beta of 1.065, which suggesting that the stock is 6.549% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $93.9M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Accuray, Inc.'s net income of -$21.7M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.24x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -23.08% compared to Accuray, Inc.'s net margin of 17.41%. Accuray, Inc.'s return on equity of -33.8% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Accuray, Inc. has a consensus price target of $3.88, signalling upside risk potential of 293.2%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 23.5%. Given that Accuray, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Accuray, Inc. is more attractive than West Pharmaceutical Services, Inc..

Accuray, Inc. has a beta of 1.065, which suggesting that the stock is 6.549% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Accuray, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Accuray, Inc. quarterly revenues are $93.9M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Accuray, Inc.'s net income of -$21.7M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while West Pharmaceutical Services, Inc.'s PE ratio is 41.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.24x versus 6.77x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -23.08% compared to Accuray, Inc.'s net margin of 3.93%. Accuray, Inc.'s return on equity of -33.8% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Accuray, Inc. has a consensus price target of $3.88, signalling upside risk potential of 293.2%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Accuray, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Accuray, Inc. is more attractive than Xtant Medical Holdings, Inc..

Accuray, Inc. has a beta of 1.065, which suggesting that the stock is 6.549% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $93.9M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Accuray, Inc.'s net income of -$21.7M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.24x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.